Hansa Biopharma AB (publ) (STO:HNSA)

Hansa Biopharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-807.24	-831.72	-611.13	-548.28	-420.85
Depreciation & Amortization	10.09	10.74	9.96	6.51	7.67
Other Amortization	17.98	9.05	2.09	2.09	-
Stock-Based Compensation	31.69	60.64	58.23	56.62	43.35
Other Operating Activities	136.64	-15.8	16.69	-1	0.24
Change in Accounts Receivable	-66.94	-35.07	-33.25	-9.6	0.41
Change in Accounts Payable	-49.35	24.49	9.12	28.58	-23.9
Change in Other Net Operating Assets	52.26	22.01	45.56	-16.09	102.81
Operating Cash Flow	-674.88	-755.65	-502.73	-481.17	-290.27
Capital Expenditures	-0.12	-0.28	-3.33	-2.4	-0.29
Investment in Securities	-	-	232.64	-	182.83
Investing Cash Flow	-0.12	-0.28	229.31	-2.4	182.53
Long-Term Debt Issued	-	-	736.4	-	-
Long-Term Debt Repaid	-7.5	-7.55	-6.89	-4.86	-4.67
Total Debt Repaid	-7.5	-7.55	-6.89	-4.86	-4.67
Net Debt Issued (Repaid)	-7.5	-7.55	729.51	-4.86	-4.67
Issuance of Common Stock	372.15	-	415.95	-	1,112
Other Financing Activities	-17.85	-	-27.78	-	-41.26
Financing Cash Flow	346.81	-7.55	1,118	-4.86	1,066
Foreign Exchange Rate Adjustments	1.42	-0.64	0.58	0.4	-0.5
Net Cash Flow	-326.78	-764.12	844.84	-488.02	957.67
Free Cash Flow	-675	-755.94	-506.06	-483.57	-290.57
Free Cash Flow Margin	-394.01%	-563.74%	-327.50%	-1427.38%	-4764.97%
Free Cash Flow Per Share	-10.74	-14.39	-11.27	-10.87	-6.89
Cash Interest Paid	-	-	1.17	-	-
Cash Income Tax Paid	3.61	0.13	1.57	0.14	0.11
Levered Free Cash Flow	-541.48	-438.91	-282.34	-257.8	-196.46
Unlevered Free Cash Flow	-457.68	-372.96	-255.05	-257.36	-196.3
Change in Net Working Capital	122.54	-41.37	-38.07	-17.04	-18.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.